A detailed history of Vanguard Group Inc transactions in Cor Medix Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,902,530 shares of CRMD stock, worth $23.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,902,530
Previous 2,928,186 0.88%
Holding current value
$23.4 Million
Previous $12.4 Million 1.22%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$4.08 - $6.39 $104,676 - $163,941
-25,656 Reduced 0.88%
2,902,530 $12.6 Million
Q1 2024

May 10, 2024

BUY
$2.94 - $4.24 $302,381 - $436,088
102,851 Added 3.64%
2,928,186 $12.4 Million
Q4 2023

Feb 14, 2024

BUY
$3.0 - $4.01 $523,761 - $700,093
174,587 Added 6.59%
2,825,335 $10.6 Million
Q3 2023

Nov 14, 2023

BUY
$3.6 - $4.46 $350,823 - $434,631
97,451 Added 3.82%
2,650,748 $9.81 Million
Q2 2023

Aug 14, 2023

BUY
$3.94 - $5.8 $2.43 Million - $3.57 Million
615,536 Added 31.77%
2,553,297 $10.1 Million
Q1 2023

May 15, 2023

BUY
$3.22 - $4.61 $452,200 - $647,405
140,435 Added 7.81%
1,937,761 $8.02 Million
Q4 2022

Feb 10, 2023

BUY
$2.81 - $4.45 $2,304 - $3,649
820 Added 0.05%
1,797,326 $7.58 Million
Q3 2022

Nov 14, 2022

BUY
$2.82 - $7.52 $399,030 - $1.06 Million
141,500 Added 8.55%
1,796,506 $5.08 Million
Q2 2022

Aug 12, 2022

SELL
$2.73 - $5.61 $434,804 - $893,499
-159,269 Reduced 8.78%
1,655,006 $6.65 Million
Q1 2022

May 13, 2022

SELL
$3.83 - $6.24 $25,756 - $41,964
-6,725 Reduced 0.37%
1,814,275 $9.94 Million
Q4 2021

Feb 14, 2022

BUY
$4.47 - $5.56 $44,941 - $55,900
10,054 Added 0.56%
1,821,000 $8.29 Million
Q3 2021

Nov 12, 2021

BUY
$4.46 - $7.11 $315,857 - $503,530
70,820 Added 4.07%
1,810,946 $8.42 Million
Q2 2021

Aug 13, 2021

BUY
$6.05 - $10.09 $10.5 Million - $17.6 Million
1,740,126 New
1,740,126 $11.9 Million

Others Institutions Holding CRMD

About CorMedix Inc.


  • Ticker CRMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,208,200
  • Market Cap $332M
  • Description
  • CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...
More about CRMD
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.